AU2016270428B2 - Endostatin fragments and variants for use in treating fibrosis - Google Patents

Endostatin fragments and variants for use in treating fibrosis Download PDF

Info

Publication number
AU2016270428B2
AU2016270428B2 AU2016270428A AU2016270428A AU2016270428B2 AU 2016270428 B2 AU2016270428 B2 AU 2016270428B2 AU 2016270428 A AU2016270428 A AU 2016270428A AU 2016270428 A AU2016270428 A AU 2016270428A AU 2016270428 B2 AU2016270428 B2 AU 2016270428B2
Authority
AU
Australia
Prior art keywords
endostatin
seq
fibrosis
polypeptide
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016270428A
Other languages
English (en)
Other versions
AU2016270428A1 (en
Inventor
Carol FEGHALI-BOSTWICK
Matthew MCGEE
Hal S. Padgett
Terence E. Ryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Novici Biotech LLC
Ibio Inc
Original Assignee
MUSC Foundation for Research and Development
Novici Biotech LLC
Ibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and Development, Novici Biotech LLC, Ibio Inc filed Critical MUSC Foundation for Research and Development
Publication of AU2016270428A1 publication Critical patent/AU2016270428A1/en
Application granted granted Critical
Publication of AU2016270428B2 publication Critical patent/AU2016270428B2/en
Priority to AU2021200765A priority Critical patent/AU2021200765B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2016270428A 2015-06-05 2016-06-03 Endostatin fragments and variants for use in treating fibrosis Ceased AU2016270428B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021200765A AU2021200765B2 (en) 2015-06-05 2021-02-05 Endostatin fragments and variants for use in treating fibrosis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562171889P 2015-06-05 2015-06-05
US62/171,889 2015-06-05
US201562257607P 2015-11-19 2015-11-19
US62/257,607 2015-11-19
PCT/US2016/035858 WO2016197018A1 (en) 2015-06-05 2016-06-03 Endostatin fragments and variants for use in treating fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021200765A Division AU2021200765B2 (en) 2015-06-05 2021-02-05 Endostatin fragments and variants for use in treating fibrosis

Publications (2)

Publication Number Publication Date
AU2016270428A1 AU2016270428A1 (en) 2018-01-25
AU2016270428B2 true AU2016270428B2 (en) 2020-11-26

Family

ID=56236074

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016270428A Ceased AU2016270428B2 (en) 2015-06-05 2016-06-03 Endostatin fragments and variants for use in treating fibrosis
AU2021200765A Ceased AU2021200765B2 (en) 2015-06-05 2021-02-05 Endostatin fragments and variants for use in treating fibrosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021200765A Ceased AU2021200765B2 (en) 2015-06-05 2021-02-05 Endostatin fragments and variants for use in treating fibrosis

Country Status (10)

Country Link
US (2) US10844392B2 (enExample)
EP (1) EP3303383A1 (enExample)
JP (2) JP6952685B2 (enExample)
KR (1) KR20180033499A (enExample)
CN (2) CN115925878A (enExample)
AU (2) AU2016270428B2 (enExample)
BR (1) BR112017026209A2 (enExample)
CA (1) CA2988299C (enExample)
WO (1) WO2016197018A1 (enExample)
ZA (1) ZA201708223B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016270428B2 (en) 2015-06-05 2020-11-26 Musc Foundation For Research Development Endostatin fragments and variants for use in treating fibrosis
AU2019338416A1 (en) * 2018-09-14 2021-04-29 Akso Biopharmaceutical, Inc. sPD-1 variant - Fc fusion proteins
EP3996736A4 (en) * 2019-07-10 2023-05-24 Musc Foundation for Research Development ENDOSTATIN PEPTIDES FOR THE TREATMENT OF TUMOR, FIBROSIS AND ACUTE LUNG INJURY
EP3996694A1 (en) * 2019-07-31 2022-05-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptides as inhibitors of fibrotic matrix accumulation
JP7493945B2 (ja) * 2020-01-28 2024-06-03 ポーラ化成工業株式会社 培養組織の観察方法、培養方法、評価方法及び培養器具
WO2022006601A1 (en) * 2020-07-02 2022-01-06 Northwestern University Human recombinant ace2-fc mutants that decouple anti-sars-cov-2 activity from cardiovascular effects

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050311A1 (en) * 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US750375A (en) 1904-01-26 Potato-digger
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
WO1991000916A2 (en) 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5756671A (en) 1994-06-02 1998-05-26 Mitotix, Inc. CDC37 cell-cycle regulatory protein, and uses related thereto
US6080560A (en) * 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6165460A (en) 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
DE19535939A1 (de) 1995-09-27 1997-04-03 Agfa Gevaert Ag Fotografisches Material
WO1999029855A1 (en) 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Mutants of endostatin, 'em 1' having anti-angiogenic activity and methods of use thereof
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
KR20010052566A (ko) * 1998-06-03 2001-06-25 윌리엄 뉴 엔도스타틴 단백질을 포함하는 단백질 올리고머 조성물 및이의 사용방법
AU4859399A (en) 1998-07-02 2000-01-24 President And Fellows Of Harvard College Compositions and methods for treating papillomavirus-infected cells
JP2003517280A (ja) 1999-02-05 2003-05-27 トーマス・ジェファーソン・ユニバーシティ トランス相補性システムを用いての植物における生物医学用ペプチド及びタンパク質の生成
WO2000046380A2 (en) 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US7491509B2 (en) 2003-02-03 2009-02-17 Fraunhofer Usa, Inc. System for expression of genes in plants
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
EP2173377B1 (en) * 2007-06-26 2017-11-29 University of Miami Antibody-endostatin fusion protein and its variants
CN106478776A (zh) * 2011-07-19 2017-03-08 特拉索斯创新公司 抗纤维化肽及其在用于治疗以纤维化为特征的疾病和病症的方法中的用途
AU2016270428B2 (en) 2015-06-05 2020-11-26 Musc Foundation For Research Development Endostatin fragments and variants for use in treating fibrosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050311A1 (en) * 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis

Also Published As

Publication number Publication date
CN107849117A (zh) 2018-03-27
CA2988299A1 (en) 2016-12-08
CA2988299C (en) 2023-10-31
BR112017026209A2 (pt) 2018-11-27
WO2016197018A1 (en) 2016-12-08
CN107849117B (zh) 2022-08-26
AU2016270428A1 (en) 2018-01-25
US20180179263A1 (en) 2018-06-28
EP3303383A1 (en) 2018-04-11
CN115925878A (zh) 2023-04-07
AU2021200765A1 (en) 2021-03-04
US11912755B2 (en) 2024-02-27
WO2016197018A8 (en) 2017-07-13
ZA201708223B (en) 2018-11-28
KR20180033499A (ko) 2018-04-03
WO2016197018A9 (en) 2017-01-19
JP2018524019A (ja) 2018-08-30
JP7404320B2 (ja) 2023-12-25
US20210108221A1 (en) 2021-04-15
JP2022002527A (ja) 2022-01-11
AU2021200765B2 (en) 2023-04-13
JP6952685B2 (ja) 2021-10-20
US10844392B2 (en) 2020-11-24

Similar Documents

Publication Publication Date Title
US11912755B2 (en) Endostatin fragments and variants for use in treating fibrosis
US8487072B2 (en) Compounds for stimulating P-glycoprotein function and uses thereof
US10695404B2 (en) Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
AU2019366366B2 (en) Therapeutic combinations of TDFRPs and additional agents and methods of use
KR101958964B1 (ko) 항종양 및 항혈관생성 활성을 갖는 사이클릭 펩타이드
US20220280619A1 (en) Dna vaccine against amyloid-beta and tau
CN114846020B (zh) 逆向-反转肽
JP6570511B2 (ja) アポリポタンパク質模倣体及びその使用
EP2797617B1 (en) Anti-tumor adjuvant therapy
JP2019503341A (ja) 植物細胞に生物学的に封入された、治療用タンパク質の、疾患の治療のための関心のある細胞型への標的化された送達
CN116615436A (zh) 一种含有二硫键且具有抑制丝氨酸蛋白酶活性的多肽、其衍生的杂交肽及其应用
US20180244792A1 (en) Anti-fibrotic effect of cd70
KR20160135742A (ko) 고리형 아펠린 유사체
CN113164552B (zh) 使用神经介素肽减少2型细胞因子介导的炎症的方法
JP2012512183A (ja) 改変された孔形成性タンパク質プロアエロリシンを用いた前立腺炎の処置のための方法
JP2023507793A (ja) 大環状ペプチド
WO2005095443A1 (ja) ペプチド改変を利用したドラッグデリバリーシステム
CN109476702B (zh) 肽及其用途
CA3212468A1 (en) Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis
EA011325B1 (ru) Высокоэффективные полные и частичные агонисты и антагонисты рецептора ноцицептина/орфанина fq
WO2017112549A1 (en) Dkk2 cysteine rich domain 2 containing proteins and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)